 advantag beta blocker antiarrhythm agent calcium antagonist secondari prevent myocardi infarct patient equal myocardi infarct high risk sudden death reinfarct risk ventricular eject fraction myocardi ischemia asymptomat high-dens complex prematur ventricular contract present beta blocker agent incid sudden death reinfarct survivor myocardi infarct MI first year benefici effect reduct heart rate effect absent deleteri beta blocker mark sympathomimet activ effect beta blocker ventricular fibril prematur ventricular contract trial calcium antagonist drug effect mortal rate diverg effect beta blocker calcium antagonist unexplain due part lack bradycardiac effect calcium antagonist differ effect differ calcium antagonist data trial class agent agent depress cardiac conduct devoid effect modest increas mortal result cardiac arrhythmia suppress trial class agent suppress prematur ventricular contract survivor acut MI mortal flecainid suppress prematur ventricular contract increas mortal rate due mark proarrhythm effect data class uncertain preliminari data class iii antiarrhythm agent agent blocker potenti mortal survivor MI evolv data suggest secondari prevent morbid event survivor acut MI focu antiarrhythm agent conduct beta blocker antifibrillatori action prolong refractori